Work

The role of MED12 in tumorigenesis

Year: 2016
Type: dissertation
Study design: Observational Study
Abstract: Mediator complex subunit 12 (MED12) is a component of the conserved Mediator complex and an important player in the regulation of general and gene specific transcription. Somatic MED12 mutations were associated with human tumorigenesis for the first time when exome sequencing of uterine leiomyomas identified highly specific mutations affecting exon 2 in as many as 70% of the tumors. Uterine leiomyomas are benign smooth muscle tumors estimated to affect up to 77% of reproductive-age women. Most of the tumors are sporadic, but uterine leiomyomas are also a feature of hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC), where biallelic inactivation of fumarate hydratase (FH) is driving the tumorigenesis. The overall aim of this thesis project was to take forward the finding of MED12 as a novel driver gene in myomagenesis and to analyze its role in other tumor types. Comprehensive MED12 exon 2 mutation screening in various tumor types identified mutations recurrently in uterine leiomyosarcoma and rarely in colorectal cancer. Findings demonstrate that these specific mutations are not restricted to benign tumors and suggest a possibility of some leiomyosarcomas to develop via benign leiomyoma precursor. Mutation analysis of MED12 exon 1 from tumor types where mutations in exon 2 have previously been reported revealed small in-frame deletions only in conventional uterine leiomyomas. Mutations in exon 1 led to similar global expression profile and mechanistic effects as previously observed with exon 2 mutations further emphasizing the role of MED12 in leiomyomagenesis. Assessment of the FH status and MED12 exon 1/2 mutation screening confirmed that biallelic FH inactivation and MED12 mutations are mutually exclusive both within HLRCC syndrome-associated and sporadic uterine leiomyomas. These results and the gene expression profiling of the tumors show that there are at least two distinct molecular mechanisms behind the development of uterine leiomyomas in HLRCC patients: biallelic FH inactivation and somatic MED12 mutations. A systematic database search identified few MED12 mutations affecting the leiomyoma-linked mutation hotspots in chronic lymphocytic leukemia (CLL), the most common form of leukemia in adults. Mutation screening of more than 700 samples revealed CLL as the first extrauterine cancer where specific MED12 exon 1 and 2 mutations have been observed at significant frequency. Furthermore, MED12 mutations associated with unmutated status of immunoglobulin heavy chain variable genes and elevated expression of 70 kD zeta-associated protein; well-characterized markers of poor prognosis in CLL. Functional analysis of the unusual MED12 exon 1 nonsense mutation identified in a patient with T cell acute lymphoblastic leukemia showed that mutant messenger ribonucleic acid escapes nonsense mediated decay and produces an N-terminally truncated protein. Mutation prevented protein s nuclear localization and prohibited its interactions with other Mediator complex components, which led to an identification of a nuclear localization signal occurring at the highly conserved N-terminal region of MED12. The results of this study further strengthen the role of MED12 in the pathogenesis of uterine leiomyomas. These findings demonstrate that MED12 mutations are not restricted to benign hormone-dependent solid tumors, but can be found also in malignant tumors and in hematological diseases. Our results also provide new knowledge about the structure and normal functions of the MED12 protein.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2546831269
Cites: 357
Cited by: 1
Related to: 10